Sangart - Top 20 VC deals of 2007

Company: Sangart
Based: San Diego, CA
Raised: $50M
Round: Sixth
Investors: Undisclosed Corporate Investor

Scoop: Sangart is currently conducting Phase III trials of its lead product candidate, Hemospan, a hemoglobin-based oxygen carrier designed to serve as an alternative to blood transfusions. The trials are designed to gauge the ability of Hemospan to prevent and treat hemodynamic instability, especially hypotension, or low blood pressure, during orthopedic surgery and will include more than 800 patients.

More News:
Sangart garners $50M in VC. Report

Sangart - Top 20 VC deals of 2007
Read more on

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.